The concept of essential medicines: lessons for rich countries

Hans V Hogerzeil

*BMJ* 2004;329:1169-1172
doi:10.1136/bmj.329.7475.1169

Updated information and services can be found at:
http://bmj.com/cgi/content/full/329/7475/1169

These include:

**Data supplement**

*References w1 - w10*
http://bmj.com/cgi/content/full/329/7475/1169/DC1

**References**

This article cites 8 articles, 6 of which can be accessed free at:
http://bmj.com/cgi/content/full/329/7475/1169#BIBL

2 online articles that cite this article can be accessed at:
http://bmj.com/cgi/content/full/329/7475/1169#otherarticles

**Rapid responses**

4 rapid responses have been posted to this article, which you can access for free at:
http://bmj.com/cgi/content/full/329/7475/1169#responses

You can respond to this article at:
http://bmj.com/cgi/eletter-submit/329/7475/1169

**Email alerting service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Topic collections**

Articles on similar topics can be found in the following collections

- Regulation (628 articles)
- Guidelines (461 articles)
- Global health (1618 articles)
- Resource allocation (including rationing) (262 articles)

**Notes**

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to *BMJ* go to:
http://bmj.bmjjournals.com/subscriptions/subscribe.shtml
The concept of essential medicines: lessons for rich countries
Hans V Hogerzeil

Industrialised countries, faced with increasing demands for quality health care by ageing populations and ever increasing costs of medicines, can learn from low income countries how to respond to pharmaceutical policy issues in a comprehensive way.

Since the 1970s many developing countries have started national programmes for essential drugs to promote the availability, accessibility, affordability, quality, and rational use of medicines. The cornerstones of such programmes are the careful selection of essential medicines for public supply and reimbursement, based on a systematic review of comparative efficacy, safety, and value for money; evidence based national clinical guidelines as the basis for training and rational prescribing; and a national medicines policy to balance conflicting policy objectives and to express government commitment to a common goal. Industrialised countries would do well to consider and adopt these approaches, which have been so beneficial to developing countries.

The concept of essential medicines

The concept of essential medicines was launched in 1977 with the publication of the first World Health Organization’s Model List of Essential Medicines. Since then the list has been revised every two years. Both its content and the process by which it is updated are intended as a model for developing countries. Twenty five years later the original concept is seen as a breakthrough in international public health.1 By the turn of the century, 156 mostly developing countries have a national list of essential medicines, two thirds of which have been updated in the past five years. Lists of essential medicines are also used by Unicef, the United Nations high commissioner for refugees, and many non-governmental organisations.

Selection is a two step process

Within a country, the selection of essential medicines is a two step process. Regulatory approval is usually based on a review of efficacy, safety, and quality without comparison with other medicines. From these registered products, essential medicines within a therapeutic class are then selected on the basis of comparative efficacy, safety, and cost (“value for money”). National lists of essential medicines are used to guide the procurement and supply of medicines in the public sector, reimbursement schemes, medicine donations, and local production of medicine; they also help define the training of health workers. In short, lists of essential medicines provide the scientific and public health basis for focus and expenditure in the pharmaceutical sector.

Important changes to WHO Model List

In 2002, WHO completed a rigorous overhaul of the process to update the Model List.1 An important change was that affordability changed from a precondition into a consequence of the selection. For example, before 2002, effective but expensive medicines, such as single dose azithromycin for trachoma, were not listed because of their price. Under the new definition (box 1), 12 antiretroviral medicines for HIV/AIDS were listed, irrespective of high cost. Their listing now implies that these medicines should become affordable to all patients who need them.

Advantages of clinical guidelines and lists

Good evidence shows that clinical guidelines and lists of essential medicines, when properly developed, introduced, and supported, improve prescribing quality and lead to better health outcomes.2-6 But there is also an economic argument. Firstly, in developing countries pharmaceuticals are the second biggest budget line in the health system, after salaries. Secondly, new essential medicines are expensive. For example, even with good differential pricing, lumefantrine-artemisinine is 25 times more expensive than chloroquine, the first line antimalarial it is supposed to replace; atovaquone-proguanil is about 400 times as expensive. Life saving antiretroviral combinations cost £83-£138 ($150-$250; €119-€199) per year whereas 38 countries have less than £1 per person per year available for all medicines.7 The selection of new essential medicines for public supply, subsidy, or reimbursement has enormous financial implications for developing countries.

The advantages of limited lists are therefore both medical and economical. From a medical point of view
they lead to better quality of care and better health outcomes and help focus quality control, drug information, prescriber training, and medical audit. Economically they lead to better value for money, to lower costs through economies of scale, and to simplified systems of procurement, supply, distribution, and reimbursement.

In many countries it has taken several years and several editions of treatment guidelines and lists of essential medicines to develop a more or less stable product accepted by most prescribers and used for training, procurement, and supply. Although time consuming, the wide involvement of a large number of prescribers, academic departments, health facilities, and professional organisations is crucial. It is also important to stress that essential medicines are not second rate medicines for poor people, but that they represent the most cost effective treatments for a given condition. Over time, prescribers increasingly recognise and trust the value of the clinical guidelines.

Is the concept of essential medicines relevant for rich countries?

Problems of increasing demand and rising medicine costs are not limited to developing countries. Pharmaceutical expenditure in the United States rose by 18% in 1999, 16% in 2000, and 17% in 2001. This rise is due to an ageing population, direct to consumer advertising, and, especially, the increased average cost of medicines (volume rose with only 5-6% per year over the same period). In Canada the average cost per prescription rose by 93% between 1987 and 1993. One third of this rise was due to price increases of existing medicines and 15% to increased quantities per prescription, but 55% was the result of use of new medicines. As most of the cost increases seem linked to the introduction of new medicines, systematic selection becomes important for industrialised countries as well. The decision is easy when new medicines are better and cheaper; but when they are only slightly more effective and much more expensive, the perceived advantages should be balanced against the extra cost. As most supply or reimbursement schemes operate within capped budgets, providing an expensive new medicine to one patient may imply that a clinically equivalent but cheaper medicine can not be given to several others.

The challenge to get the best value for money was common in developing countries, but is increasingly obvious in middle income situations as well. For example, there were acute problems in the supply of medicines in the Commonwealth of Independent States after the collapse of the former Soviet Union, and two years ago in Argentina. But even developed countries are increasingly following the same approach. Australia has become very strict about the selection of pharmaceuticals for reimbursement in their Pharmaceutical Benefits Scheme; in the United States most health management organisations use a restricted list of pharmaceuticals for reimbursement. What started in countries such as Cuba (1963), Tanzania (1970), and Peru (1972) and was initially (in 1978) called “desert island drugs”, is now relevant for us all.

The link with national clinical guidelines

These first essential medicines’ lists of the 1970s were often just commonsense stock lists for supply systems for the public sector. Over the years the selection criteria have become more systematic, and currently medicines are only listed when they feature in a clinical guideline. The evidence is then linked to the treatment, not to the medicine. For example, azithromycin is now on the model list for single dose treatment of genital Chlamydia trachomatis and trachoma only and not as a general antibiotic, for which its advantages are much less clear. By the turn of the century, 135 countries had developed national clinical guidelines, mostly linked to national lists of essential medicines. Good examples are Zimbabwe, South Africa and, more recently, Delhi State Capital Territory.

It has long been thought that national clinical guidelines were only relevant and, indeed, only possible in developing countries (perhaps with the exception of the antibiotic guidelines of Australia). But in the early 1990s, discrepancies in the quality of care between the various districts and hospitals in Scotland led the Department of Health and the Royal Colleges to start the Scottish Intercollegiate Guidelines Network (SIGN). This network has now prepared over 70 guidelines for disorders where treatments showed large differences despite the availability of good clinical evidence. In other developed countries the number of clinical guidelines is also growing rapidly. Unfortunately their scientific evidence base and management of potential conflicts of interests are not always transparent. This has led to international groups, such as the AGREE (Appraisal of Guidelines Research and Evaluation) collaboration to standardise the guideline development process, GRADE (the Working Group on Grading Harmonization) to standardise the grading of evidence, and GIN (the Guidelines International Network) to exchange evidence tables. What started in New Guinea (1974) and Mozambique (1981) is now happening in industrialised countries.

National medicine policies

Different objectives of a national pharmaceutical programme are often contradictory. For example, reimbursement restrictions may lead to irrational alternative prescribing, and preference for the national
pharmaceutical industry may result in higher prices for medicines. A national medicines' policy, when developed in a consultative way, helps to bring out and resolve such diverging interests. The policy then becomes the expression of government commitment to a common goal and a framework for action. In 1982, Bangladesh was the first country with a national drug policy, focusing on promoting the national drug industry; India followed soon after. The 1988 policy of the Philippines focused on generic prescribing and was widely opposed by the international pharmaceutical industry and the medical profession. The 1996 policy of South Africa focuses on equity. By the turn of the century, 109 developing countries had developed a national medicines' policy.

In industrialised countries the picture is different. Components of a pharmaceutical policy are often in place but are rarely dealt with systematically; from a public health point of view the end result is rarely satisfactory. For example, in the United States over 40 million people are not covered by health insurance, but efforts to create a national health service stranded in opposition by various stakeholders. In the United Kingdom, recommendations by the National Institute for Clinical Excellence may result in the reimbursement of new therapies; but this has an impact on district budgets for which NICE is not responsible. A suggestion in this journal to develop a national drug policy for the United Kingdom has not been taken up.

Box 2: Components of a national medicine policy potentially relevant for developed countries

- Additional criteria for market approval (comparison with best available treatment, comparative cost effectiveness, price, regional harmonisation)
- Evidence based national clinical guidelines (for training, prescribing, and audit)
- Insurance and reimbursement (systematic evidence based selection of treatments for reimbursement; type and level of reimbursement focused on essential medicines)
- State subsidies (direct supply, subsidy or subsidised insurance for poor and disadvantaged people; access to essential medicines as part of human rights; sex equity)
- Price controls (taxes and margins on essential medicines, dispensing fees, reference pricing)
- Local production versus importation
- Patent policies (balance between innovation and equitable access to essential medicines)
- Quality (quality control, counterfeits, quality of the distribution chain)
- Rational prescribing (training; financial incentives, separated prescribing and dispensing; audit)
- Rational use by the public (public education; medicine information)
- Promotion (regulation, monitoring, conflict of interest in prescribing and research)
- Human resources (number of pharmacists, technicians, and dispensers needed over time)
- Research and development (public support for public health priorities)

Comprehensive national pharmaceutical policies may therefore also be helpful in industrialised countries (box 2). Australia was in such a situation, with four good but separate programmes for improving the availability, quality, and quality use of medicines and the viability of the national pharmaceutical industry. In 2000 the National Drug Policy of Australia was launched, bringing these successful components together into one government paper. Many observers think that this was partly due to the political pressure by national experts and non-governmental organisations that had assisted developing countries with the establishment of such policies.

Conclusion

The selection of essential medicines based on sound scientific review and public health grounds, the development of evidence based national clinical guidelines and a national medicines' policy are the cornerstones of any essential medicines' programme. Although some of these components may be in place, industrialised countries would do well to consider in a more systematic way these comprehensive approaches that have proved so beneficial to developing countries.

I thank Kath Hurst and Shalini Jayasekar for support and Richard Laing and James Tumwine for their comments. Important WHO references to support the selection of essential medicines are: 13th model list of essential medicines (www.who.int/medicines); WHO model formulary 2004 (mednet3.who.int/eml/modelFormulary.asp); and the WHO essential medicines library (mednet3.who.int/eml/).

Contributors: HVH is the sole contributor to this article.

Funding: Department of Essential Drugs and Medicines Policy, WHO.

Competing interests: None declared

Commentary: The pros and cons of essential medicines for rich countries

Marcus M Reidenberg, Tom Walley

Rising costs of drugs is universal. From 1998 to 2001, prescription costs in the United States and England increased by 62% and 30%, respectively. Could the essential drugs concept help rich countries to control the rise in drug costs? Hogerzeil\(^1\) cites Australia as an example, although experience there is hardly encouraging: spending on medicines rose by 69% between 1998 and 2002,\(^2\) and the political difficulties of the process have been widely reported.\(^3\) But containing costs is not the only aim of the essential drugs concept, which primarily aims to increase access and efficiency and to promote better health and equity. These are also aims in rich countries, which already apply many of the principles of the concept, both to improve care and to manage costs.

The treatment of rheumatoid arthritis illustrates the problem. In the United States, pain and inflammation can be suppressed by ibuprofen at about $4 per month (£2.46 in the UK NHS). The disease process can be slowed with methotrexate at about $50 per month. Outcome may further be improved by using leflunomide, $270 per month, or etanercept, $1210 per month.\(^4\)

Clinical and economic evaluation of new medicines is part of approval for reimbursement in, for instance, Australia, and effectively in the United Kingdom through the National Institute for Clinical Excellence. But in neither country has this controlled rises in expenditure. Essential drug lists or formularies are already widespread in rich countries—for example, in hospitals, in health maintenance organisations in the United States, and in primary care in the United Kingdom. But there are trade-offs: limitations on choice of drug may save money, but if rigorously applied, some patients will be affected.

In developing countries, people may accept restrictions in return for wider access. In rich countries, where access to most drugs is already wide, people may question the need for restriction except perhaps for very high cost drugs, with discretion on grounds of exceptional need. A rigid nationally imposed list would probably not be acceptable and might be ignored by the private sector. Ultimately, how much a country spends on publicly funded medicines is a value or policy judgment.

Drug lists need integration into clinical guidelines, which can improve care but not necessarily cut costs. In the United Kingdom, National Institute for Clinical Excellence guidelines and setting national standards have increased prescribing costs. Implementing guidelines is difficult, but information technology may help.\(^5\) Limiting the influence of pharmaceutical companies on doctors and patients is difficult.

The essential drugs concept expects affordability to follow drug selection, hoping that a manufacturer of an expensive drug will trade a higher volume of sales for a lower cost or be forced by law or public opinion to reduce costs or relax patent protection. This has worked for antiretroviral drugs, but manufacturers can still make profits in rich countries. If rich countries played the same game, would drug development, usually funded from drug sales, slow? A new paradigm of sharing risk between commercial drug developers and public funders would be necessary. Furthermore, many rich countries are major exporters of pharmaceuticals, which bring employment and wealth. Restricting access to new drugs in a home market would not sit well with their industrial policies.

So although the principles of the essential drugs concept are generally accepted and elements applied in rich countries, national application is unlikely to achieve the medical, policy, and industrial aims of these countries. We should learn from the experience of those implementing the concept, but adaptation must be sensitive to different environments.

Competing interests: None declared.